Advertisement

Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report

Abstract

Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of advanced stage non-small cell lung cancer (NSCLC). Clinical trials have shown high efficacy of erlotinib, particularly in patients harboring activating mutations in the EGFR gene. Here we describe the case of a 42-year-old female light smoker diagnosed with EGFR mutation-positive adenocarcinoma of the left lung with pleural metastases, pleural effusion and metastases to the thoracic vertebrae (stage IV, T4NXM1). Although the patient developed resistance to erlotinib in the first line, she achieved disease stabilization lasting for 13 months as a response to erlotinib retreatment after 6 cycles of second-line chemotherapy. In conclusion, retreatment with erlotinib in our patient was effective. Therefore it should be considered as a good treatment option for patients with NSCLC harboring EGFR mutation.

Tumori 2014; 100(3): e70 - e73

Article Type: CASE REPORT

DOI:10.1700/1578.17234

Authors

Ondrej Fiala, Milos Pesek, Jindrich Finek, Gabriela Krakorova, Lucie Benesova, Marek Minarik

Article History

This article is available as full text PDF.

Download any of the following attachments:

Authors

  • Fiala, Ondrej [PubMed] [Google Scholar]
    Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University, Prague, Czech Republic
  • Pesek, Milos [PubMed] [Google Scholar]
    Department of Tuberculosis and Respiratory Diseases, Medical School and Teaching Hospital Pilsen, Charles University, Prague, Czech Republic
  • Finek, Jindrich [PubMed] [Google Scholar]
    Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University, Prague, Czech Republic
  • Krakorova, Gabriela [PubMed] [Google Scholar]
    Department of Tuberculosis and Respiratory Diseases, Medical School and Teaching Hospital Pilsen, Charles University, Prague, Czech Republic
  • Benesova, Lucie [PubMed] [Google Scholar]
    Center for Applied Genomics of Solid Tumors (CEGES), Genomac Research Institute, Prague, Czech Republic
  • Minarik, Marek [PubMed] [Google Scholar]
    Center for Applied Genomics of Solid Tumors (CEGES), Genomac Research Institute, Prague, Czech Republic

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.